Comments (11) LIgorko/iStock via Getty Images Leading drugmakers, including AbbVie (ABBV), Bristol Myers Squibb (BMY), Gilead (GILD), and Merck (MRK), will be among the latest to announce agreements with the Trump administration to cut prices of certain prescription drugs Post navigation Following Medtronic, J&J nets liquid embolic nod in subdural hematomaBioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
